Healthcare / BiotechnologyNasdaqCM
$0.92
-0.01 (-1.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.9M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-919.3%
↓Gross Margin
N/A
•Debt/Equity
0.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-8.2M · FCF $-7.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | $58000.00 | $477000.00 | $1.4M | — | — | — | — | $479000.00 | $576000.00 | $904000.00 | — | — | — | $12000.00 | $0.00 |
| Net Income | $-8.2M | $-8.2M | $-7.9M | $-11.6M | $-11.9M | $-12.6M | $-15.0M | $-14.7M | $-14.0M | $-12.3M | $-10.3M | $-6.7M | $234000.00 | $19000.00 | $305000.00 | $9.7M | $-11.5M |
| EBITDA | $-8.3M | $-8.3M | $-7.9M | $-11.6M | $-11.8M | $-12.6M | $-15.5M | $-14.1M | $-14.0M | $-12.3M | $-7.6M | $-5.4M | — | — | — | $-618000.00 | $384000.00 |
| EPS | -1.23 | -1.23 | -2.90 | -8.19 | -10.05 | -11.25 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — |
| Operating Margin | — | — | -13794.8% | -2441.1% | -880.3% | — | — | — | — | -2589.8% | -1320.8% | -598.3% | — | — | — | -5150.0% | — |
| Net Margin | — | — | -13700.0% | -2425.8% | -880.7% | — | — | — | — | -2569.5% | -1789.9% | -740.8% | — | — | — | 80516.7% | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.59 | 0.59 | 1.14 | -0.82 | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.41 | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-7.4M | $-7.4M | $-7.9M | $-10.0M | $-10.6M | $-10.5M | $-12.4M | $-9.6M | $-11.1M | $-8.8M | — | $-7.1M | — | — | $-310000.00 | $-3.2M | $-5.3M |
| Returns | |||||||||||||||||
| ROE | -919.3% | -919.3% | -949.3% | 721.8% | -243.4% | -121.7% | -78.2% | -620.6% | -368.9% | -110.6% | -50.1% | 194.6% | -0.5% | 0.1% | 2.3% | 74.4% | -351.0% |
| Valuation | |||||||||||||||||
| P/B | 6.85 | 6.85 | 7.57 | — | 8.66 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | -87.8% | -64.7% | — | — | — | — | — | -16.8% | -36.3% | — | — | — | — | — | — |
| EPS Growth | 57.6% | 57.6% | 64.6% | 18.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.90 → -1.23
Residual
-57.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.